

May 29, 2026

To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 15/26-27	Our Reference No. 15/26-27

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30, we wish to inform you that the Board of Glenmark Pharmaceuticals Limited (the "Company"), at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ("**GHL**"), a wholly owned subsidiary of the Company.

As required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the requisite information is enclosed herewith as Annexure A.

You are requested to kindly take note of the same.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure A
Details which a listed entity needs to disclose for Sale or disposal of unit(s) or division(s) or subsidiary of the listed entity under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Particulars	Remarks
a) the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	For the nine months ended December 31, 2025, the Nebulizer business recorded revenue of Rs. 71.6 Cr, representing approx. 1.3% of the Company's standalone revenue for the corresponding period. Net worth of GHL business as on March 31, 2026 was about negative Rs. 9.9 Crore.
b) date on which the agreement for sale has been entered into	1 st June 2026
c) the expected date of completion of sale/disposal	Expected to be completed on or before 30 th June 2026.
d) consideration received from such sale/disposal	The brands/ IP portfolio transfer is expected to be carried out at a cash consideration of Rs. 223 Cr based on the Independent Valuer report.
e) brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	The buyer is GHL, a wholly owned subsidiary of the Company, having its registered office at Glenmark House, B.D. Sawant Marg, Chakala, Andheri (East), Mumbai - 400099, India.
f) name of the entity(ies), details in brief such as, size, turnover etc.	GHL is engaged in manufacturing of pharmaceutical products.
g) whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes. The transaction is with a related party and is done at arm's length.
h) area of business of the entity(ies)	Manufacturing and marketing of Pharmaceutical Products.
i) rationale	The Nebulizer business segment is registering robust growth across India and Emerging Markets, offering a significant opportunity to scale. The Company aims to transfer the complete ownership of its Nebulizer brands/IP portfolio to GHL. GHL is in the process of setting up a new dedicated Nebulizers manufacturing facility wherein these products will be manufactured. The proposed structure will enable sharper strategic focus, greater operational agility, and long-term value creation for all stakeholders. The subsidiary will also house a portfolio of innovative Nebulizers including the world's first nebulized triple therapy for Chronic Obstructive Pulmonary Disease (COPD), further consolidating Glenmark's leadership in respiratory innovation and its commitment to making advanced, affordable, and accessible solutions for patients.

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

j) in case of cash transaction – amount or otherwise share exchange ratio	Please refer clause (d) above.
k) Brief details of change in shareholding (if any) of listed entity	No change in the shareholding pattern of the Company.

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com